Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Outstanding (Weighted Average) (2022 - 2025)

Atara Biotherapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $12.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 67.52% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $12.5 million, up 67.52%, while the annual FY2025 figure was $12.5 million, 67.52% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $12.5 million in Q4 2025 per ATRA's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $105.1 million in Q2 2023 to a low of $2.5 million in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $31.1 million, with a median of $9.1 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 97.51% in 2023, then soared 153.79% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $102.0 million in 2022, then plummeted by 95.85% to $4.2 million in 2023, then surged by 76.77% to $7.5 million in 2024, then skyrocketed by 67.52% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Shares Outstanding (Weighted Average) are $12.5 million (Q4 2025), $13.6 million (Q3 2025), and $12.2 million (Q2 2025).